Imagion Biosystems Ltd. has released a press release.
IBX Phase 2 Clinical Trial Update
Earlier from Imagion Biosystems
- Appendix 4C and Quarterly Activities Report - June 2026
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- IBX Secures Firm Commitments for $3.75m for Clinical Trial
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review